Sleep Laboratory Studies of Hypnotic Drugs: Efficacy and Withdrawal Effects
The DOI matches its Crossref record.
Abstract
Flurazepam, temazepam, and triazolam are compared in terms of initial and short term efficacy, effectiveness during intermediate and long term use, withdrawal effects, and general side effects. The usefulness of temazepam is considerably restricted since the drug is slowly absorbed; peak blood concentrations are not reached until 2 to 3 hours after ingestion. Consequently, while the majority of insomniac patients complain primarily of difficulty falling asleep, temazepam is not effective for this sleep complaint. Further, the drug has an intermediate elimination half-life and induces a significant degree of morning sleepiness (hang-over). Rebound insomnia of a moderate degree occurs with some frequency following withdrawal of temazepam. Triazolam is effective initially and with short term use both for inducing and maintaining sleep. However, much of this effectiveness is lost with continued nightly use over an intermediate period (2 weeks). The drug has a rapid elimination rate; during drug administration, sleep may worsen in the final hours of the night (early morning insomnia), and following drug withdrawal, rebound insomnia is frequent, immediate, and severe. Side effects are frequent and include some morning sleepiness (before tolerance develops) and significant memory impairment and even episodes of amnesia. Triazolam may have a narrow margin of safety in that serious behavioral symptoms have been reported even with a 1-mg dose. Flurazepam is effective both for initiating and maintaining sleep with initial and short term drug administration. Further, its efficacy is maintained not only with intermediate term use but with long term drug use (4 weeks). Flurazepam is a long elimination half-life drug, and there is significant daytime sedation during short term use; with continued use this effect diminishes. Rebound insomnia has not been noted following withdrawal of flurazepam; there is a carry-over effectiveness into the first and second nights of withdrawal, and any withdrawal sleep disturbance would be expected to be infrequent, delayed in appearance, and mild in degree.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Flurazepam, which has a relatively long elimination half-life, was shown to be effective for initiating and maintaining sleep with intermediate and long-term use (over 4 weeks), even though daytime sedation diminished during prolonged use [47].”
From Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective Receptor Modulators? (2012) · cites this paper as [47]
Citations
Cites
Still being checked.
Cited by
Sensitivity to triazolam in the elderly
Greenblatt, D. J., Harmatz, J. S., Shapiro, L., Engelhardt, N., Gouthro, T. A., & Shader, R. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106133242403 · Cited by 258
Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?
Lader, M. H. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00051-6 · Cited by 220
Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond
Licata, S. C., & Rowlett, J. K. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.01.001 · Cited by 197
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195
“Flurazepam, which has a relatively long elimination half-life, was shown to be effective for initiating and maintaining sleep with intermediate and long-term use (over 4 weeks), even though daytime sedation diminished during prolonged use [47].”
BackgroundSpielman, A. (1986) · Clinical Psychology Review · doi:10.1016/0272-7358(86)90015-2 · Cited by 192
Metadata
- Authors
- KALES, A., & KALES, J. D.
- Affiliations
- Pennsylvania State University (US)
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1983-04
- Volume
- 3
- Issue
- 2
- Pages
- 140
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2045912535
- Cited by
- 61
- References
- 0
- Citations by year
- 2023: 2 · 2015: 1 · 2013: 1 · 2012: 2
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- hypnotics, flurazepam, temazepam, triazolam, rebound insomnia, drug withdrawal effects, insomnia, sleep maintenance, daytime sedation, memory impairment, adverse drug reactions, elimination half-life, drug absorption
- MeSH terms
- Antidepressive Agents, Tricyclic, Anxiety, Dose-Response Relationship, Drug, Flurazepam, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Sleep, Substance Withdrawal Syndrome, Temazepam, Anti-Anxiety Agents, Triazolam
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sleep Laboratory Studies of Hypnotic Drugs: Efficacy and Withdrawal Effects. https://app.cochat.ai/papers/10.1097/00004714-198304000-00038
- The paper
- KALES, A., & KALES, J. D. (1983). Sleep Laboratory Studies of Hypnotic Drugs: Efficacy and Withdrawal Effects. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-198304000-00038
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.